

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (HI-142) ZIMBERELIMAB

PRONUNCIATION zim" ber el' i mab

THERAPEUTIC CLAIM Antineoplastic

CHEMICAL NAMES

1. Immunoglobulin G4[231-proline], anti-(human programmed cell death protein 1) (human monoclonal AB122 γ 4-chain), disulfide with human monoclonal AB122 λ -chain, dimer
2. immunoglobulin G4-lambda, anti-(*Homo sapiens* Programmed cell death protein 1 (hPD-1, CD279-antigen)); *Homo sapiens* monoclonal antibody; γ 4 heavy chain *Homo sapiens* (1-450) [VH (*Homo sapiens* IGHV4-39*01 (88%) – (IGHD)-IGHJ4*01) [10.7.15] (1-123) -*Homo sapiens* IGHG4*01 {hinge[S¹⁰>P(231)]} (124-450)] (137-215')-disulfide with λ light chain *Homo sapiens* (1'-216') [V-LAMBDA (*Homo sapiens* IGLV2-14*03 (96%) – IGLJ3*02)[9.3.10] (1'-110') -*Homo sapiens* IGLC2*01 (111'-216')], dimer (229-229":232-232")-bisdisulfide, produced in CHO-K1 cell line, glycoform alfa. Post-translational modifications: K(450) and K(450") deleted, N(300) and N(300") glycosylated

STRUCTURAL FORMULA

Heavy chain X & X"

QLQLQESGPG	LVKPSETLTL	TCTVSADSI	STYYVWVIR	QPPGKLEWI	50
GSISYSGSTY	YNPSLKSRTV	VSVDTSKNQF	SLKLNSVAAT	DTALYYCARH	100
LGYNRYLPPF	DYWGQGLVLT	VSSASTKGPS	VFPLAPCSRS	TSESTAALGC	150
LVKDYFPEPV	TVSWNSGALT	SGVHTFPAVL	QSSGLYSLSS	VVTVPSSSLG	200
TKTYTCNVDH	KPSNTKVDKR	VESKYGPPCP	PCPAPEFLGG	PSVFLFPPKP	250
KDTLMISRTP	EVTCTVVVDV	QEDPEVQFNW	YVDGVEVHNA	KTKPREEQFN	300
STYRVVSVLT	VLHQDWLNGK	EYKCKVSNKG	LPSSIEKTIS	KAKGQPREPQ	350
VYTLPPSQEE	MTKNQVSLTC	LVKGFYPSDI	AVEWESNGQP	ENNYKTTTPV	400
LDSDGSFFLY	SRLTVDKSRW	QEGNVFSCSV	MHEALHNHYT	QKSLSLSLGK	450

Light chain X' & X'''

QSALTQPASV	SGSPGQSITI	SCTGTSSDVG	FYNYVSWYQQ	HPGKAPELMI	50'
YDVSNRPSGV	SDRFSGSKSG	NTASLTISGL	QAEDEADYYC	SSYTSISTWV	100'
FGGGTKLTVL	GQPKAAPSVT	LFPPSSEELQ	ANKATLVCLI	SDFYPGAVTV	150'
AWKADSSPVK	AGVETTPPSK	QSNNKYAASS	YLSLTPEQWK	SHRSYSCQVT	200'
HEGSTVEKTV	APTECS				216'

Disulfide bridges location

22'-90'	22'''-90'''	22-97	22"-97"	137-215'	137"-215'''	138'-197'	138'''-197'''
150-206	150"-206"	229-229"	232-232"	264-324	264"-324"	370-428	370"-428"

Modified residues



Glycosylation sites (N)

Asn-300 Asn-300"

MOLECULAR FORMULA	C ₆₄₃₆ H ₉₈₇₈ N ₁₆₇₄ O ₂₀₄₂ S ₄₀
MOLECULAR WEIGHT	144.66 kDa
TRADEMARK	None as yet
SPONSOR	Arcus Biosciences Inc.
CODE DESIGNATIONS	AB122; WBP3055; GLS-010
<u>CAS</u> REGISTRY NUMBER	2259860-24-5
UNII	ZBL7O904IL
WHO NUMBER	11413

gbk